{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:08:30Z","timestamp":1790485710826,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ahj.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T03:18:19Z","timestamp":1490152699000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-3135","authenticated-orcid":false,"given":"Maya","family":"Guglin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Krischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2017.03.010_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2\u2013positive early breast cancer: a meta-analysis of published randomized trials","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ahj.2017.03.010_bb0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ahj.2017.03.010_bb0015","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2017.03.010_bb0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3816\/CBC.2004.n.033","article-title":"Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer","volume":"5","author":"Tripathy","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ahj.2017.03.010_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-005-9030-x","article-title":"Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer","volume":"95","author":"Venturini","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.ahj.2017.03.010_bb0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","article-title":"Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study","volume":"15","author":"Guglin","year":"2009","journal-title":"J Card Fail"},{"issue":"23","key":"10.1016\/j.ahj.2017.03.010_bb0035","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ahj.2017.03.010_bb0040","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2017.03.010_bb0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cardfail.2008.02.002","article-title":"Trastuzumab-induced cardiomyopathy","volume":"14","author":"Guglin","year":"2008","journal-title":"J Card Fail"},{"issue":"16","key":"10.1016\/j.ahj.2017.03.010_bb0050","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ahj.2017.03.010_bb0055","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel","volume":"21","author":"Leyland-Jones","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.ahj.2017.03.010_bb0060","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3816\/CBC.2007.n.017","article-title":"Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer","volume":"7","author":"Ewer","year":"2007","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"10.1016\/j.ahj.2017.03.010_bb0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/sj.bjc.6603060","article-title":"Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study","volume":"94","author":"Bengala","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ahj.2017.03.010_bb0070","first-page":"S82","article-title":"Trastuzumab mediated cardiac dysfunction in the clinical setting","author":"Bhimaraj","year":"2008"},{"issue":"25","key":"10.1016\/j.ahj.2017.03.010_bb0075","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"10.1016\/j.ahj.2017.03.010_bb0080","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.ahj.2017.03.010_bb0085","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ahj.2017.03.010_bb0090","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","author":"Pituskin","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.ahj.2017.03.010_bb0095","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ahj.2017.03.010_bb0100","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","article-title":"Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer","volume":"19","author":"Burstein","year":"2001","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15","key":"10.1016\/j.ahj.2017.03.010_bb0105","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2003.02.018","article-title":"Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm","volume":"21","author":"Burstein","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"31","key":"10.1016\/j.ahj.2017.03.010_bb0110","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317300935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870317300935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:18Z","timestamp":1762077378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870317300935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":22,"alternative-id":["S0002870317300935"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2017.03.010","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}